Lupus Nephritis Study

GCRC 0244: A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4lg (Abatacept) Plus Cyclophosphamide Alone in the Treatment of Lupus Nephritis

Protocol ID

08-197

Protocol Description

The purpose of this study is to find out if abatacept, used with cyclophosphamide, corticosteroids and azathioprine is safe and works better in patients with lupus nephritis (inflammation in the kidneys) than standard treatment with cyclophosphamide, corticosteroids, and azathioprine therapy alone.  In other words, the researchers would like to see what effects (good or bad) abatacept has on you and other patients with Systemic Lupus Erythematosus and nephritis.  The use of abatacept with these other drugs is experimental.

Eligibility Criteria

Systemic lupus erythematosus patients with active nephritis (inflammation in the kidneys)

Primary Investigator(s)

  • Meggan Mackay, MD

Contact Information

Andrew Shaw
(516) 562-2591
anshaw@nshs.edu

Last Update

April 2, 2010
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Lupus:
top